Literature DB >> 18027222

Adaptive seamless designs: selection and prospective testing of hypotheses.

Christopher Jennison1, Bruce W Turnbull.   

Abstract

There is a current trend towards clinical protocols which involve an initial "selection" phase followed by a hypothesis testing phase. The selection phase may involve a choice between competing treatments or different dose levels of a drug, between different target populations, between different endpoints, or between a superiority and a non-inferiority hypothesis. Clearly there can be benefits in elapsed time and economy in organizational effort if both phases can be designed up front as one experiment, with little downtime between phases. Adaptive designs have been proposed as a way to handle these selection/testing problems. They offer flexibility and allow final inferences to depend on data from both phases, while maintaining control of overall false positive rates. We review and critique the methods, give worked examples and discuss the efficiency of adaptive designs relative to more conventional procedures. Where gains are possible using the adaptive approach, a variety of logistical, operational, data handling and other practical difficulties remain to be overcome if adaptive, seamless designs are to be effectively implemented.

Mesh:

Year:  2007        PMID: 18027222     DOI: 10.1080/10543400701645215

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  15 in total

1.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Using Bayesian modeling in frequentist adaptive enrichment designs.

Authors:  Noah Simon; Richard Simon
Journal:  Biostatistics       Date:  2018-01-01       Impact factor: 5.899

3.  Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment.

Authors:  M Rosenblum; M J Van der Laan
Journal:  Biometrika       Date:  2011-12       Impact factor: 2.445

4.  Inference for multimarker adaptive enrichment trials.

Authors:  Richard Simon; Noah Simon
Journal:  Stat Med       Date:  2017-08-10       Impact factor: 2.373

5.  Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial.

Authors:  Jordan J Elm; Yuko Y Palesch; Gary G Koch; Vanessa Hinson; Bernard Ravina; Wenle Zhao
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

6.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

7.  Adaptive Enrichment Designs in Clinical Trials.

Authors:  Peter F Thall
Journal:  Annu Rev Stat Appl       Date:  2021-03       Impact factor: 7.917

8.  Confidence intervals for the selected population in randomized trials that adapt the population enrolled.

Authors:  Michael Rosenblum
Journal:  Biom J       Date:  2013-04-03       Impact factor: 2.207

Review 9.  Integrated phase II/III clinical trials in oncology: a case study.

Authors:  Meihua Wang; James J Dignam; Qiang E Zhang; John F DeGroot; Minesh P Mehta; Sally Hunsberger
Journal:  Clin Trials       Date:  2012-11-22       Impact factor: 2.486

Review 10.  Experimental designs for small randomised clinical trials: an algorithm for choice.

Authors:  Catherine Cornu; Behrouz Kassai; Roland Fisch; Catherine Chiron; Corinne Alberti; Renzo Guerrini; Anna Rosati; Gerard Pons; Harm Tiddens; Sylvie Chabaud; Daan Caudri; Clément Ballot; Polina Kurbatova; Anne-Charlotte Castellan; Agathe Bajard; Patrice Nony; Leon Aarons; Agathe Bajard; Clément Ballot; Yves Bertrand; Frank Bretz; Daan Caudri; Charlotte Castellan; Sylvie Chabaud; Catherine Cornu; Frank Dufour; Cornelia Dunger-Baldauf; Jean-Marc Dupont; Roland Fisch; Renzo Guerrini; Vincent Jullien; Behrouz Kassaï; Patrice Nony; Kayode Ogungbenro; David Pérol; Gérard Pons; Harm Tiddens; Anna Rosati; Corinne Alberti; Catherine Chiron; Polina Kurbatova; Rima Nabbout
Journal:  Orphanet J Rare Dis       Date:  2013-03-25       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.